Application of mirtazapine and methotrexate combined medicine to preparation of medicine for treating liver cancer

A technology of methotrexate and treatment of liver cancer, which is applied in the field of medicine to achieve the effects of reducing dosage, enhancing curative effect and improving anti-tumor effect

Inactive Publication Date: 2021-03-05
阿耳法猫(杭州)人工智能生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no reports on the combined effect of mirtazapine and methotrexate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mirtazapine and methotrexate combined medicine to preparation of medicine for treating liver cancer
  • Application of mirtazapine and methotrexate combined medicine to preparation of medicine for treating liver cancer
  • Application of mirtazapine and methotrexate combined medicine to preparation of medicine for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 MTT method to detect the sensitivity of different liver cancer cells to mirtazapine

[0024] 1. Experimental materials

[0025] (1) Drug: The chemical structural formula of mirtazapine is as follows:

[0026]

[0027] (2) Liver cancer cells: human liver cancer cells HEPG2 cells and SMMC-7721 cells.

[0028] (3) Commercially available MTT kits.

[0029] 2. Experimental grouping

[0030] (1) Control group: blank control, that is, the liver cancer cells were not treated with any drugs.

[0031] (2) Experimental group: Liver cancer cells were treated with different concentrations of mirtazapine.

[0032] 3. MTT method to detect the sensitivity of different tumor cells to mirtazapine

[0033] (1) Human liver cancer cells HEPG2 cells and 7761 cells were inoculated into 96-well plates at the number of 5000-9000 cells per well. After the cells adhered to the wall, PBS solutions of different concentrations of mirtazapine were added. After culturing for 24 hour...

Embodiment 2

[0035] Example 2 Effects of methotrexate alone or in combination with mirtazapine and methotrexate on the inhibition rate of liver cancer cells

[0036] 1. Experimental materials

[0037] (1) Drugs: mirtazapine, methotrexate.

[0038] (2) Liver cancer cells: human liver cancer cells HEPG2 cells and SMMC-7721 cells.

[0039] (3) Commercially available MTT kits.

[0040] 2. Experimental grouping

[0041] (1) Control group: liver cancer cells were only treated with methotrexate.

[0042] (2) Experimental group: Different concentrations of mirtazapine and methotrexate were used in combination to treat liver cancer cells.

[0043] 3. MTT method to detect the sensitivity of liver cancer cells to the combination of mirtazapine and methotrexate

[0044] (1) Human liver cancer cell HEPG2 cells and SMMC-7721 cells were inoculated into 96-well plates at the number of 5000-9000 cells per well. After the cells adhered to the wall, different ratios of mirtazapine and methotrexate were ...

Embodiment 3

[0046] Example 3 Effects of methotrexate alone or in combination with mirtazapine and methotrexate on the inhibition rate of human liver cancer tissue organoids

[0047] 1. Experimental materials

[0048] (1) Drugs: mirtazapine, methotrexate.

[0049] (2) Liver cancer cells: human liver cancer tissue organoids.

[0050] (3) Commercially available CellTiter-Glo 3D kit.

[0051] 2. Experimental grouping

[0052] (1) Control group: treated only with methotrexate.

[0053] (2) Experimental group: Different concentrations of mirtazapine and methotrexate were used in combination to treat human liver cancer tissue organoids.

[0054] 3. Sensitivity of human liver cancer tissue organoids to the combination of mirtazapine and methotrexate

[0055] (1) Mix the treated human liver cancer cells with Matrigel Matrigel, add 50 μl of mixed Mtrigel Matrigel to each well on a 48-well plate, add 250 μl complete medium to each well after gel formation, and place at 37°C, Cultured in a cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and particularly relates to an application of a mirtazapine and methotrexate combined medicine to preparation of a medicine for treating liver cancer.According to the invention, the application of the mirtazapine and methotrexate combined medicine to preparation of the medicine for treating liver cancer is proposed for the first time, mirtazapine and the methotrexate have an obvious synergistic effect, the curative effect is effectively improved, compared with a single component, for the mirtazapine and methotrexate combined medicine, the curative effect is more remarkable, and the lethality to tumor cells is improved. The dosage is effectively reduced, so that the toxic and side effects are reduced. The mirtazapine and methotrexate combined medicine can also save cost, reduce economic burden of patients, provide a new approach for prevention and treatment of liver cancer, and have broad application prospects in the field of medicine and pharmacology.

Description

technical field [0001] The invention belongs to the field of medicine, and particularly relates to the application of mirtazapine and methotrexate in the preparation of drugs for treating liver cancer. Background technique [0002] Liver cancer is one of the common malignant tumors in my country, which can be divided into two categories: primary and secondary. Liver cancer cells have strong proliferative ability, and tumor nodules can reach more than ten centimeters. At the same time, they are highly metastatic. They can metastasize not only in the liver, but also to extrahepatic tissues. The most common metastases are lungs, and they can also metastasize to adrenal glands, bones, and kidneys. , brain, etc. At present, the treatment methods for liver cancer are still based on surgery, radiotherapy, and chemotherapy, and the curative effect has not yet made breakthrough progress. [0003] Methotrexate is a folate reductase inhibitor, which is an anti-folate antineoplastic d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P35/00A61K31/519
CPCA61K31/519A61K31/55A61P35/00A61K2300/00
Inventor 李斌
Owner 阿耳法猫(杭州)人工智能生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap